As a key mid-stage readout approaches for the group’s neoantigen immunotherapy, Gritstone still has much to prove.

The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.

Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.

Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.

After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.

Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.